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Abstract. This study was conducted on thirteen bitches, with clinical suspicion of 
breast cancer. Excisional tumors obtained by surgery methods were subjected to 
histopathological and immunohistochemical exams was preceded by preoperative clinical and 
thermographic examination. The purpose of this research was to study the correlation between 
histology and immunohistochemistry techniques for characterization and selection of a battery 
of biomarkers useful in the management of canine mammary tumors, the model determined in 
human clinical practice. A goal of this work was also to evaluate the immunohistochemical 
techniques used in human oncology for the characterization of prognostic markers in 
veterinary oncological value. In this research were analyzed a series of markers of epithelial, 
myoepithelial, and neuroendocrine proliferation, summarizing the results of 
immunohistochemical techniques in our casuistry, the techniques used in humans could be 
extrapolated successfully in canine pathology for AE1/AE3 (pancitokeratina), Ck5/6, SMA, 
CD56, Ki67. Immunohistochemical techniques and histopathological diagnosis can increase 
accuracy without additional information on tumor aggressiveness and prognosis, in 
conjunction with your class and clinical pathology. 
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INTRODUCTION 
 
Mammary tumors are the most common form of tumors in canine females, with an 
incidence of 198.8%000 relative frequency  and 7 times higher than in cats, that is 5 times the 
human species. The increased incidence is related, unfortunately, with a reserved prognosis or 
serious in some cases, illustrated by the figures of mortality. Median survival is 28 months for 
small tumors and decreases to 5 months for cases with haematogenous metastases. 
Assuming that the management of mammary tumors in canines is a priority in 
veterinary pathology and oncology, we considered that the approach to mammary tumors in 
 261 
dogs is a challenge, a vast field of systematization and improvement of veterinary practice, 
and not least a duty to patients affected by this relatively common and very serious suffering. 
Currently the canine species there is no effective screening methods generally accepted, 
immunohistochemical techniques in addition to classical histological examination are not part 
of routine diagnosis of these disorders, and surgery remains the main method of treatment, 
whose effectiveness remains limited to benign tumors and localized to the malignant without 
negative prognostic factors. 
This paper aims to address some current issues in diagnosis and prognosis of canine 
mammary tumors using casuistry cdrul diagnosed and treated in the Clinic of Reproduction, 
Obstetrics and Gynecology Faculty of Veterinary Medicine in Cluj, between 2009 and 2011. 
 
MATERIALS AND METHODS 
 
Between february 2009 - march 2011 were included in the study a total of thirteen 
females of canine species, which were presented for diagnosis and treatment in the clinic of 
the Department of Reproduction, Obstetrics and Gynecology, Faculty of Veterinary Medicine 
Veterinary Cluj. Inclusion criteria were: female sex canine showing clinical suspicion of 
mammary tumors (palpable nodule at one or more mothers, with / without palpable regional 
adenopathy). Spare breast biopsy / mastectomy from surgery performed were sent for routine 
histopathological examination of histo-pathology laboratory of the Faculty of Veterinary 
Medicine Cluj and Cluj Santomar laboratory for performing the histopathological 
examination and immunohistochemical techniques complementary. Histopathological 
examination of samples obtained was preceded by clinical and thermographic examination of 
each patient in order to confirm the initial diagnostic.  
 
   Positive diagnosis and extension balance focused on the following steps: 
       -  history (talk to the owner): history, character family search forms; 
       -  general exam; 
       -  clinical examination and palpation of mammary glands axillary and inguinal   
           lymph node regions; 
        - pre-thermographic examination (taken with your ThermaCAM PM695); 
        - surgery protocol (to specify the location and size of tumor, type of intervention  
           and its macroscopic margins); 
        -confirmation of positive diagnosis by histopathological and  imunohistochemical 
          results. 
 
RESULTS AND DISCUSSIONS 
 
From February 2009 to March 2011 were included in the study a total of thirteen 
bitches.  
Characteristics of patients are presented in table 1. Of these, three cases had clinical 
examination in the mammary gland tumor and a case without palpable tumor (control), made 
a thermography screening compared with images obtained from bitches with mammary 
neoplastic pathology. 
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Table 1. 
Individual characteristics of patients examined during this study 
 
No. Breed Ag
e 
Wei
ght 
Dg. 
Termogra
phy 
Surgery** Rezultat HP 
1 Common 
breed 
9 15 No Unilateral 
mastectomy  
Carcinoma 
2 Common 
breed 
10 18 No Unilateral 
mastectomy 
TMM-Epit 
3 German 
shepard 
11 32 No Unilateral 
mastectomy 
TMB 
4 German 
shepard 
12 25 Yes Unilateral 
mastectomy 
TMM-Src 
5 Cocker  
spaniel 
8 13 No Unilateral 
mastectomy 
 Inflamatory  
carcinoma  
6 German 
shepard 
10 24 No Bilateral 
mastectomy 
Carcinoma 
7 Common 
breed 
6 19 Yes Unilateral 
mastectomy 
TMB + 
Adenoma 
8 Cocker  
spaniel 
11 14 No  Bilateral 
mastectomy 
TMB 
9 Common 
breed 
10 6 No Unilateral 
mastectomy 
Carcinoma 
10 Common 
breed 
14 4 No Unilateral 
mastectomy 
Carcinoma 
11 Bull 
terrier 
12 14 Yes Unilateral 
mastectomy 
Cutaneus  
fibroma 
12 Basset  
Hound 
12 26 No Unilateral 
mastectomy 
Malign  
tumora 
13  Husky 5 21 Yes - Without tumors 
 
In an attempt to characterize the canine mammary tumors immunohistochemically in 
the present work we studied the expression following graduation markers on mammary tumor 
biopsy tracks: 
Epithelial markers: Pan-citokeratina AE1/AE3, CK 5 / 6, CK 7, EMA (epithelial membrane 
antigen) 
Myoepithelial markers: CD10, S100, smooth muscle actin (SMA, smooth muscle actin) 
Neuro-endocrine markers:  
CD56 
Hormone receptors: RE (estrogen receptor) and PR (progesterone receptor) 
Proliferation markers:  
Ki67 
Other tumor markers: HER-2, EGFR, p53 
 
          General remarks:  
          Were processed 11 mammary tumors from 11 patients noted C1-C11 canine.  
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Maximum size ranged from 1 cm to 2,5 cm in diameter. Positive microscopic surgical 
margins appear (R1) to six/ twelve cases. Some malignant tumors had a monomorphic 
appearance, others are composed of different cellular elements, in very different proportions 
from one tumor to another (mixed tumors). By comparison mixed breast tumors in humans 
contain only two elements proliferate: epithelial cells and stromal cells. Thus the term "fibro-
epithelial tumors": fibroadenoma (benign). Unlike the human mammary tumors, canine 
tumors can be classified as "mixed tumors" because they are composed of:  
          1. epithelial cell lights; 
          2. myoepithelial cells "basal"; 
          3. stromal cells. 
         Mixed mammary tumors to the dogs seem to resemble more like the human salivary 
gland tumors, where you can find "mixed tumors" with three components such as 
pleomorphic adenoma (benign). 
        Theoretically, any of the three components of canine mammary tumors can be malignant: 
        - epithelial compound => carcinoma (in situ <invasive); 
        - stromal compound => sarcoma;  
        - myoepithelial compound => myoepithelial malignant tumor ("myoepithelial  
          carcinoma"). 
        The tumors examined was very difficult to determine the tumor is benign and malignant 
epithelial compound and if malignant was difficult to assess whether the tumor is invasive or 
not. 
 
Table 2. 
Histopathological and immunohistochemical markers results 
 
 C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 C11 
Histological 
type  Adenocc  TMM-Ep TMB TMM-Str Carcinoma  Carcinoma TMB/Ad TMB Carcinoma Carcinoma Fibroma 
ER 0 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
PR 0 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
HER2 scor 0 scor 0 scor 0 scor 0 scor 0 scor 0 scor 0 scor 0 scor 0 scor 0 scor 0 
EGFR 1+ 1+/ 2+ neg - neg - 3+ 2+ neg- 2+ neg neg neg 
Ki67 35% 10% 15% 6% 80% 30% 0% 5% 25% 5% 0% 
p53 0 1% 0 5% 70% 1% 0% 5% 0% 0% 0% 
Ck 
AE1/AE3 poz poz.  poz.  neg poz poz poz poz poz poz neg 
Ck7 neg N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Ck5/6 
focal + 
CE intens+CE  intens+CE  neg poz poz poz poz poz poz neg 
EMA N/A neg neg. N/A N/A N/A N/A N/A N/A N/A N/A 
S100 N/A neg neg. N/A N/A N/A N/A N/A N/A N/A N/A 
Actina SM 
poz. 
CME poz. CME poz. CME poz. CME poz.CME poz.CME pozCME poz poz poz neg 
CD10 poz.  poz.  poz.  poz.inomogen focal poz focal poz poz poz poz poz neg 
CD56 
focal 
poz. neg Intens ++ intens ++ focal p+ focal + neg - 
Weak 
positive focal + Neg - Neg- 
 
Summarizing the results, we draw the following conclusions: 
          Histological type  was noted and analyzed in detail in 11/12 cases (91.6%) in a case 
diagnosed in another department with only an indication of malignant mammary tumors. 
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From case studies analyzed, 8 / 12 (66.6%) had malignant tumors and 4 / 12 (33.3%) benign 
tumors. Histological types found were: 
 
         - carcinoma in 5 cases (41.6%) and 1 case (8.3%) unspecified malignant tumor; 
         -  malignant mixed tumors, 2 cases (16.6%) (1 with malignant component of carcinoma  
             and 1 with malignant component of sarcoma); 
         -  benign mixed tumors, in 3 cases (25%); 
         -  benign tumors in a single case (8.3%) (1 fibroids skin); 
         -   malignancy without further specification, 1 case (8.3%). 
 
 
 
Fig.1. Case 1 -  Adenocarcinoma, in situ component, solide type, CK 100x 
 
 
 
Fig.2. Case 1 - Adenocarcinoma, , col. IHC pentru CK, 100x 
 
Epithelial markers: Pan-citokeratina AE1/AE3 was positive in all cases of carcinoma 
(5 cases), benign mixed tumors with predominance of epithelial component (1 case), benign 
mixed tumors (3 cases), being negative in 2 cases (1 case of malignant mixed tumor with 
malignant component of sarcoma and 1 case of fibroids). 
         Ck 5/6, positivity of this test is similar in casuistry analyzed for pancitokeratină test 
described above, Ck 5 / 6 was positive diffuse or focal epithelial component in all cases of 
carcinoma (5 cases), benign mixed tumors with predominance of component epithelium (1 
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case), benign mixed tumors (3 cases), being negative in 2 cases (1 case of malignant mixed 
tumor with malignant component of sarcoma and 1 case of fibroids). 
 
 
 
Fig.3. Case 1, IHC stain for CK5/6,  reveals the cells from the basal 
and superficial  leyer in blood vessels proliferation 
 
Ck 7 is completely negative in all sections tested, unlike humans, which is highly positive 
breast carcinomas. 
EMA (epithelial membrane antigen) does not work the dog is completely negative in all 
sections tested. 
                 Myoepithelial markers: 
                CD10, which in humans is a marker of basal myoepithelial cells and marks the 
lumen of glandular structures and some epithelial cells isolated from the surface. Therefore, 
although it was positive in ten cases, can not effectively be used as basal cell marker in canine 
pathology. CD10 was negative in the case of fibroids. 
              S100, which in humans is a marker of myoepithelial basal cells, the canine was 
negative (or in any case is highlighted by the antibody used). In conclusion, it can be used as a 
basal myoepithelial cell marker. 
             Smooth muscle actin (SMA) works very well to canine, as in humans, and can be 
used as a basal myoepithelial cell marker. This marker is useful for identification of invasive 
(when the myoepithelial layer disappears). It could be identified in all cases, unless the 
fibroids skin. 
Neuro-endocrine markers: 
CD56 marks verry intense many epithelial structures, particularly the duct lumen, as sarcoma 
components (which raised suspicion of a neuroendocrine differentiation in two of the cases 
analyzed). Seems to be a useful marker for detecting neuroendocrine component in canine 
steroido-dependent tumors. It was intensely positive in 2 cases of mixed tumors (benign 
mixed tumor and a mixed sarcoma malignant tumor), focal positive and 4 cases of carcinoma 
in 1 case of weak positive benign mixed tumor. It was negative in 4 cases (1 malignant mixed 
tumor carcinoma, 1 adenoma, 1 carcinoma, 1 fibroma). 
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Fig.4. Case 1, IHC stain pentru neuro-endocrine marker, CD56  
reveals a focal positivity in itraductal area, 100x 
 
Hormone receptors: RE (estrogen receptor) and PR (progesterone receptor) - techniques used 
in human clinical determining estrogen and progesterone receptor status could not be 
extrapolated successfully to canine mammary pathology and were non-contributory. 
Proliferation markers : 
Ki67 works very well in canine and marks proliferating cells nuclei. The results of 
measurements are presented în table  2. 
Ki67 value was zero for benign tumors (adenoma and one case of fibroids). 
Mixed tumors had a mean of 7.2% Ki67. It is noted that the mixed tumors had averages close 
Ki67, whether benign or have only been histologically had a malignant component. Thus, 
benign mixed tumors had values of 0, 5% and 15% (average 6.66%) and malignant mixed 
tumors values, 6% and 10% (average 8%). 
 
 
 
Fig.5. Case 4, - IHC Stain for Ki67; 
observed several positive tumor nuclei, 200x 
 
 
Mono-type carcinoma malignant tumors had proliferation indices of 30%, 35%, 80%, 
25% and 5%, which is the average of the high (35%). This tendency to correlate with 
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histological carcinoma Ki67 values suggest a good marker of proliferation applicability of this 
trend to characterize aggressiveness of tumors analyzed. 
 
Other tumor markers 
HER2 score was 0-10 cases and 1 + / 2 + in a single case of malignant mixed tumor, which 
does not allow statements on the usefulness of determining the canine breast tumors. 
EGFR, the reaction was intensely positive (or quantified 2 + 3 +) in 3 cases (two with 
carcinoma and 2 cases of mixed tumors). The other two cases were weakly positive reaction 
(adenocarcinoma and malignant mixed epithelial tumor). EGFR was negative in 6 cases (2 
cases of carcinoma, a benign mixed tumor, 1 mixed tumor sarcomatoasă, 1 adenoma, 1 
fibroma). In conclusion, IHC technique used enabled the identification of EGFR protein 
supraexpresion prognostic role of EGFR but not determined. 
Reaction positivity for p53 suppressor gene was quantified according to the percentage of 
positive nuclei. Positivity ranged from 70% nuclei in a case of carcinoma, 5% tumor nuclei 
mixed sarcomatoşi a malignant and a benign mixed tumor, 1% for a carcinoma and malignant 
mixed epithelial tumors of a. CE was negative in 3 carcinomas, a mixed benign tumors, the 
adenomas and the fibroid. In conclusion, the technique used IHC p53 positive nuclei in the 
identification, but, as with EGFR, the prognostic role of p53 is not specified in canine breast 
tumors. 
Table 3. 
Correlation between histological features and Ki67 values 
 
Anatomopatologic type Ki 67 (%) 
Benign tumors (Fibroma, adenoma) 0 
Mixed tumors 7,2%  (TMB: 6,66%, TMM: 8%) 
Carcinoma 35% 
 
Other tumor markers 
HER2 score was 0-10 cases and 1 + / 2 + in a single case of malignant mixed tumor, which 
does not allow statements on the usefulness of determining the canine breast tumors. 
EGFR, the reaction was intensely positive (or quantified 2 + 3 +) in 3 cases (two with 
carcinoma and 2 cases of mixed tumors). The other two cases were weakly positive reaction 
(adenocarcinoma and malignant mixed epithelial tumor). EGFR was negative in 6 cases (2 
cases of carcinoma, a benign mixed tumor, 1 mixed tumor sarcomatoasă, 1 adenoma, 1 
fibroma). In conclusion, IHC technique used enabled the identification of EGFR protein 
supraexpresion prognostic role of EGFR but not determined. 
Reaction positivity for p53 suppressor gene was quantified according to the percentage 
of positive nuclei. Positivity ranged from 70% nuclei in a case of carcinoma, 5% tumor nuclei 
mixed sarcomatoşi a malignant and a benign mixed tumor, 1% for a carcinoma and malignant 
mixed epithelial tumors of a. CE was negative in 3 carcinomas, a mixed benign tumors, the 
adenomas and the fibroid. In conclusion, the technique used IHC p53 positive nuclei in the 
identification, but, as with EGFR, the prognostic role of p53 is not specified in canine breast 
tumors. 
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CONCLUSIONS 
 
• Summarizing the results of immunohistochemical techniques in our casuistry, the 
techniques used in humans could be extrapolated successfully in canine pathology for 
AE1/AE3 (pancitokeratina) Ck5 / 6, SMA, CD56, Ki67. For protein overexpression of 
EGFR and p53 positive nuclei percentage identification method used was also applicable, 
but practical use is not yet specified. 
• Determination Ck7, EMA, CD10, S100, RE and RP could not be achieved with techniques 
in use in humans, in our series and the method for HER2 gave mixed results. 
• In recent years there has been notable progress in histopathological and molecular 
characterization of breast tumors in humans (eg description of the type luminal A, luminal 
B, normal breast like, HER2 positive and basal or triple negative), applicable in veterinary 
pathology. 
• Casuistry included 12 cases of mammary tumors operated, of which eight were malignant 
and four benign proved. Histology was carcinoma (5 cases), benign mixed tumors (3 
cases), malignant   mixed tumors (2 cases), unspecified  malignant   tumor (1 case), skin 
fibroma (one case); 
• Immunohistochemical techniques were applied to 11 cases in which immunohistochemical 
stains were performed for epithelial markers (pan citokeratina AE1/AE3, CK 5 / 6, CK 7, 
EMA) myoepithelial markers (CD10, S100, smooth muscle actin - SMA) , neuro-endocrine 
markers (CD56), hormone receptors (ER - estrogen receptor and PR - progesterone 
receptor), proliferation markers (Ki67), other tumor markers (HER-2, EGFR, p53). 
• Methods used in man could be successfully extrapolated canine pathology for AE1/AE3 
(pancitokeratina) Ck5 / 6, SMA, CD 56, Ki67, p53 EGFR. 
• Determination of Ck7, EMA, CD10, S100, RE and RP could not be achieved with IHC 
methods and antibodies are in use in humans, in our series and the method for HER2 gave 
mixed results. 
 
This work was supported by CNCSIS-UEFISCSU, project PN II RU-PD code 258, 
contract no. 181/2010. 
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